Literature DB >> 32352364

Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: It Is Time to Produce Our Own Evidence Base.

Abdullah Sayıner1.   

Abstract

Entities:  

Year:  2020        PMID： 32352364      PMCID： PMC7371398          DOI： 10.5152/TurkThoracJ.2020.20.03

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN： 2148-7197


× No keyword cloud information.
  4 in total

1.  Evidence Based Treatment of SARS-CoV2: A Narrative Review.

Authors:  Sumita Agrawal; Nitesh Gupta; Akhil Dhanesh Goel
Journal:  Turk Thorac J       Date:  2020-04-16

2.  Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China.

Authors:  Xiaojing Wu; Ying Cai; Xu Huang; Xin Yu; Li Zhao; Fan Wang; Quanguo Li; Sichao Gu; Teng Xu; Yongjun Li; Binghuai Lu; Qingyuan Zhan
Journal:  Emerg Infect Dis       Date:  2020-06-17       Impact factor: 6.883

3.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Authors:  Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-20       Impact factor: 5.283

4.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.